|
Jan 24
|
Where Will CRISPR Therapeutics Be in 5 Years?
|
|
Jan 24
|
Wall Street Bulls Look Optimistic About Vertex (VRTX): Should You Buy?
|
|
Jan 24
|
2 Super Stocks You'll Wish 5 Years From Now That You'd Bought Today
|
|
Jan 23
|
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts
|
|
Jan 23
|
1 Setback and 1 Opportunity for CRISPR Therapeutics Stock
|
|
Jan 22
|
A New S&P 500 Bull Market Just Began: 3 No-Brainer Stocks to Buy Hand Over Fist
|
|
Jan 22
|
12 S&P 500 Stocks On the Move
|
|
Jan 22
|
If You Invested $10,000 in Vertex Pharmaceuticals in 2018, This Is How Much You Would Have Today
|
|
Jan 22
|
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
|
|
Jan 21
|
2 Smart Growth Stocks to Buy Hand Over Fist in 2024
|
|
Jan 20
|
3 Unstoppable Growth Stocks That Can Make You Richer in 2024
|
|
Jan 20
|
These 2 Phenomenal Growth Stocks Can Make You Richer in 2024
|
|
Jan 20
|
3 High-Flying Stocks That Could Soar Even More in 2024
|
|
Jan 16
|
Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock
|
|
Jan 16
|
UPDATE 2-US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder
|
|
Jan 16
|
Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia
|
|
Jan 15
|
Down 88%, Could Editas Medicine Be a Good Investment Now?
|
|
Jan 14
|
What Does It Mean for Investors if CRISPR Therapeutics Gets Bought Out in 2024?
|
|
Jan 14
|
My 3 Highest-Conviction Growth Stocks to Buy in 2024
|
|
Jan 14
|
3 Growth Stocks to Buy That Could Be Massive Long-Term Winners
|